85%Confidence
0Views
FDASource
2026-03-27Date
Summary
Cipla's Nilotinib Capsules recall due to stability test failures indicates potential quality control issues at their manufacturing facility in India, which could impact supply of this cancer medication and damage Cipla's reputation with US regulators. This may create opportunities for competitors in the tyrosine kinase inhibitor market but could also lead to increased FDA scrutiny of imported pharmaceuticals from this region.
Actionable: Monitor Cipla's stock for potential impact and consider alternative suppliers for nilotinib if you're in the pharmaceutical supply chain.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now